Angiolillo DJ, Galli M, Collet JP, Kastrati A, O’Donoghue ML. Antiplatelet therapy after percutaneous coronary intervention. Euro Intervention. 2022;17:e1371–96.

PubMed  Article  Google Scholar 

Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42:1289–367.

PubMed  Article  Google Scholar 

Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119–77.

PubMed  Article  Google Scholar 

Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64:e139–228.

PubMed  Article  Google Scholar 

O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the American College of Emergency Physicians and Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv. 2013;82:E1-27.

PubMed  Article  Google Scholar 

Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–57.

CAS  PubMed  Article  Google Scholar 

Steg PG, James S, Harrington RA, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation. 2010;122:2131–41.

PubMed  Article  Google Scholar 

Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010;375:283–93.

CAS  PubMed  Article  Google Scholar 

Lindholm D, Varenhorst C, Cannon CP, et al. Ticagrelor vs clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur Heart J. 2014;35:2083–93.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Gupta R, Malik AH, Briasoulis A, Joshi AM, Guthier DG, Popli T, et al. Comparative safety and effectiveness of loading doses of P2Y12 inhibitors in patients undergoing elective PCI: a network meta-analysis. Cardiovasc Drugs Ther. 2021. https://doi.org/10.1007/s10557-021-07270-3.

Zhao X, Zhang J, Guo J, et al. Comparison of safety and efficacy between clopidogrel and ticagrelor in elderly patients with acute coronary syndrome: a systematic review and meta-analysis. Front Pharmacol. 2021;12:743259.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Abusnina W, Al-Abdouh A, Bizanti A, et al. Ischemic and bleeding outcomes of potent P2Y12 inhibitor antiplatelet agents versus clopidogrel in elderly patients with acute coronary syndrome: a meta-analysis of randomized trials. Cardiovasc Revasc Med. 2022;38:54–60.

PubMed  Article  Google Scholar 

Tarantini G, Ueshima D, D’Amico G, et al. Efficacy and safety of potent platelet P2Y12 receptor inhibitors in elderly versus nonelderly patients with acute coronary syndrome: a systematic review and meta-analysis. Am Heart J. 2018;195:78–85.

CAS  PubMed  Article  Google Scholar 

Baldetti L, Melillo F, Moroni F, et al. Meta-analysis comparing P2Y12 inhibitors in acute coronary syndrome. Am J Cardiol. 2020;125:1815–22.

CAS  PubMed  Article  Google Scholar 

Hong SJ, Ahn CM, Kim JS, et al. Effect of ticagrelor monotherapy on mortality after percutaneous coronary intervention: a systematic review and meta-analysis of randomized trials including 26 143 patients. Eur Heart J Cardiovasc Pharmacother. 2022;8:48–55.

PubMed  Article  Google Scholar 

Ma Y, Zhong PY, Shang YS, et al. Comparison of ticagrelor with clopidogrel in East Asian patients with acute coronary syndrome: a systematic review and meta-analysis of randomized clinical trials. J Cardiovasc Pharmacol. 2022;79:632–40.

CAS  PubMed  Article  Google Scholar 

Sun M, Cui W, Li L. Comparison of clinical outcomes between ticagrelor and clopidogrel in acute coronary syndrome: a comprehensive meta-analysis. Front Cardiovasc Med. 2021;8:818215.

CAS  PubMed  Article  Google Scholar 

Bergh N, Myredal A, Nivedahl P, et al. Efficacy and safety of clopidogrel versus ticagrelor as part of dual antiplatelet therapy in acute coronary syndrome-a systematic review and meta-analysis. J Cardiovasc Pharmacol. 2022;79:620–31.

CAS  PubMed  Article  Google Scholar 

Mahaffey KW, Wojdyla DM, Carroll K, et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011;124:544–54.

CAS  PubMed  Article  Google Scholar 

Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–15.

CAS  PubMed  Article  Google Scholar 

Birnbaum GD, Birnbaum I, Ye Y, Birnbaum Y. Statin-induced cardioprotection against ischemia-reperfusion injury: potential drug-drug interactions. Lesson to be learnt by translating results from animal models to the clinical settings. Cardiovasc Drugs Ther. 2015;29:461–7.

CAS  PubMed  Article  Google Scholar 

Damman P, Woudstra P, Kuijt WJ, de Winter RJ, James SK. P2Y12 platelet inhibition in clinical practice. J Thromb Thrombolysis. 2012;33:143–53.

CAS  PubMed  Article  Google Scholar 

Ye Y, Birnbaum GD, Perez-Polo JR, et al. Ticagrelor protects the heart against reperfusion injury and improves remodeling after myocardial infarction. Arterioscler Thromb Vasc Biol. 2015;35:1805–14.

CAS  PubMed  Article  Google Scholar 

Wang K, Zhou X, Huang Y, et al. Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model. Thromb Haemost. 2010;104:609–17.

CAS  PubMed  Article  Google Scholar 

Audia JP, Yang XM, Crockett ES, et al. Caspase-1 inhibition by VX-765 administered at reperfusion in P2Y. Basic Res Cardiol. 2018;113:32.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Ubaid S, Ford TJ, Berry C, et al. Cangrelor versus ticagrelor in patients treated with primary percutaneous coronary intervention: impact on platelet activity, myocardial microvascular function and infarct size: a randomized controlled trial. Thromb Haemost. 2019;119:1171–81.

PubMed  Article  Google Scholar 

Allencherril J, Alam M, Levine G, et al. Do we need potent intravenous antiplatelet inhibition at the time of reperfusion during ST-segment elevation myocardial infarction? J Cardiovasc Pharmacol Ther. 2019;24:215–24.

PubMed  Article  Google Scholar 

Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357:1121–35.

CAS  PubMed  Article  Google Scholar 

Asanuma H, Kitakaze M. Is aspirin loading before primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction necessary?. Cardiovasc Drugs Ther 2022.

Ishida T, Yarimizu K, Gute DC, Korthuis RJ. Mechanisms of ischemic preconditioning. Shock. 1997;8:86–94.

CAS  PubMed  Article  Google Scholar 

Kitakaze M, Minamino T, Node K, et al. Adenosine and cardioprotection in the diseased heart. Jpn Circ J. 1999;63:231–43.

CAS  PubMed  Article  Google Scholar 

Cattaneo M, Schulz R, Nylander S. Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol. 2014;63:2503–9.

CAS  PubMed  Article  Google Scholar 

Badimon L, Vilahur G, Rocca B, Patrono C. The key contribution of platelet and vascular arachidonic acid metabolism to the pathophysiology of atherothrombosis. Cardiovasc Res. 2021;117:2001–15.

CAS  PubMed  Article  Google Scholar 

Nanhwan MK, Ling S, Kodakandla M, et al. Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect. Arterioscler Thromb Vasc Biol. 2014;34:2078–85.

CAS  PubMed  Article  Google Scholar 

Granger CB, Berger PB. Understanding the Adverse Effects of Ticagrelor in Practice. JAMA Cardiol. 2016;1.

Atar S, Ye Y, Lin Y, et al. Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2. Am J Physiol Heart Circ Physiol. 2006;290:H1960-1968.

CAS  PubMed  Article  Google Scholar 

Sanada S, Asanuma H, Minamino T, et al. Optimal windows of statin use for immediate infarct limitation: 5’-nucleotidase as another downstream molecule of phosphatidylinositol 3-kinase. Circulation. 2004;110:2143–9.

CAS  PubMed  Article  Google Scholar 

Birnbaum Y, Lin Y, Ye Y, et al. Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin. Am J Physiol Heart Circ Physiol. 2007;292:H2891-2897.

CAS  PubMed  Article  Google Scholar 

Bonello L, Laine M, Kipson N, et al. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J Am Coll Cardiol. 2014;63:872–7.

CAS  PubMed  Article  Google Scholar 

Husted S, van Giezen JJ. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther. 2009;27:259–74.

CAS  PubMed  Article  Google Scholar